Manufacturer of Controlled Substances; Notice of Registration, 6311 [E9-2538]
Download as PDF
<![CDATA[
6311
Federal Register / Vol. 74, No. 24 / Friday, February 6, 2009 / Notices
Drug
Schedule
Hydromorphone (9150) ...............................................................................................................................................................................
Diphenoxylate (9170) ..................................................................................................................................................................................
Benzoylecgonine (9180) ..............................................................................................................................................................................
Ethylmorphine (9190) ..................................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Levomethorphan (9210) ..............................................................................................................................................................................
Levorphanol (9220) .....................................................................................................................................................................................
Isomethadone (9226) ..................................................................................................................................................................................
Meperidine (9230) .......................................................................................................................................................................................
Meperidine intermediate-A (9232) ...............................................................................................................................................................
Meperidine intermediate-B (9233) ...............................................................................................................................................................
Meperidine intermediate-C (9234) ...............................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Methadone intermediate (9254) ..................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) (9273) ..............................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Levo-alphacetylmethadol (9648) .................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Noroxymorphone (9668) ..............................................................................................................................................................................
Racemethorphan (9732) ..............................................................................................................................................................................
Alfentanil (9737) ..........................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
dwashington3 on PROD1PC60 with NOTICES
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cerilliant Corporation to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Cerilliant Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 30, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–2541 Filed 2–5–09; 8:45 am]
BILLING CODE 4410–09–P
VerDate Nov<24>2008
14:16 Feb 05, 2009
Jkt 217001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated October 7, 2008 and
published in the Federal Register on
October 14, 2008, (73 FR 60719), Halo
Pharmaceutical Inc., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Schedule
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
I
II
Dihydromorphine is an intermediate
in the manufacture of Hydromorphone
and is not for commercial distribution.
The company plans to manufacture
Hydromorphone HCL for sale to other
manufacturers and for the manufacture
of other controlled substance dosage
units for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Halo
Pharmaceutical Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Halo Pharmaceutical Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: January 30, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–2538 Filed 2–5–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Employment and Training
Administration Notice of
Implementation of Supplemental
Appropriations Act, 2008, Title IV—
Emergency Unemployment
Compensation, and the Unemployment
Compensation Extension Act
AGENCY: Employment and Training
Administration, Labor.
ACTION: Notice.
SUMMARY: The Employment and
Training Administration (ETA) of the
United States Department of Labor (the
Department) is publishing, for public
information, notice of the issuance and
availability of the Unemployment
Insurance Program Letters (UIPL) that
E:\FR\FM\06FEN1.SGM
06FEN1
]]>Agencies
[Federal Register Volume 74, Number 24 (Friday, February 6, 2009)]
[Notices]
[Page 6311]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-2538]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated October 7, 2008 and published in the Federal
Register on October 14, 2008, (73 FR 60719), Halo Pharmaceutical Inc.,
30 North Jefferson Road, Whippany, New Jersey 07981, made application
to the Drug Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the basic classes of controlled substances listed in
schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
Dihydromorphine is an intermediate in the manufacture of
Hydromorphone and is not for commercial distribution. The company plans
to manufacture Hydromorphone HCL for sale to other manufacturers and
for the manufacture of other controlled substance dosage units for
distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Halo Pharmaceutical Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Halo Pharmaceutical Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: January 30, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-2538 Filed 2-5-09; 8:45 am]
BILLING CODE 4410-09-P
